Evaluation of AN777 on Elderly Subjects During Bed Rest and Recovery

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Aged

In brief

The primary objectives are to evaluate the effect of AN777 on muscle strength loss that occurs during bed rest, and to investigate whether AN777, in association with resistance training, will support muscle strength recovery following bed rest in healthy elderly subjects.

Key facts

Study ID

NCT00945581

Run by

Abbott Nutrition

People needed

36

Starts

2009-11-01

Expected to finish

2011-03-01

Last updated by the study team

2011-03-29

Who can join

Age: 60 and older, up to 79. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subject (male or female) is > 60 to < 79 years of age.
• Subject has Body Mass Index (BMI)> 20 < 35.
• Subject is ambulatory with an SPPB score of > 9.
• Subject agrees to comply with prescribed activity level.

You may not qualify if…

• Subject has undergone major surgery, less than 4 weeks prior to enrollment in the study.
• Subject has stated active malignant disease, except basal or squamous cell skin carcinoma or carcinoma in situ of the uterine cervix.
• Subject has stated history of diabetes or fasting glucose value > 126 mg/dL.
• Subject has stated presence of partial or full artificial limb.
• Subject has stated kidney disease or serum creatinine > 1.4 mg/dL.
• Subject has evidence of cardiovascular disease assessed during resting or exercise EKG.
• Subject has untreated hypothyroidism with TSH levels greater than 5.5 microUnits/ml.
• Subject has serum glutamate pyruvate transaminase (SGPT) levels greater than two times upper limit of laboratory-designated normal value.
• Subject has a history of allergy to any of the ingredients in the study products.
• Subject has an obstruction of the gastrointestinal tract precluding ingestion of the study product, inflammatory bowel disease, short bowel syndrome or other major gastrointestinal disease such as gastroesophageal reflux disease, gastroparesis, peptic ulcer disease, celiac disease, intestinal dysmotility, diverticulitis, ischemic colitis.
• Subject has stated uncontrolled severe diarrhea, nausea or vomiting.
• Subject is actively pursuing weight loss.
• Subject is currently taking medications/dietary supplements/substances that could modulate metabolism or weight in the opinion of the principal investigator or physician, e.g. progestational agents, steroids, growth hormone, dronabinol, marijuana, beta-hydroxyl-beta-methylbutyrate (HMB), free amino acid supplements, dietary supplements to aid weight loss. Exceptions for multi-vitamin/mineral supplement, inhaled steroids for asthma, topical or optical steroids and short-term use (less than two weeks) of Dexamethasone.
• Subject cannot refrain from smoking/discontinue the use of nicotine or tobacco.
• Subject has a stated history of Deep Vein Thrombosis (DVT) or a known hypercoaguable condition.
• Subject cannot discontinue current anticoagulant therapy.
• Subject has refractory anemia with hemoglobin value < 11.5 g/dL.

Where it is running

• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.